This is a recording of a session from the AMP 2019 Annual Meeting & Expo. Purchase the entire AMP 2019 Annual Meeting & Expo Recordings for a significant discount!
Numerous studies have demonstrated the value of measurable residual disease (MRD) as a prognostic marker in patients with acute leukemia. While many markers have been well-validated for this approach such as NPM1 and specific recurrent fusions, some markers such as those associated with clonal hematopoiesis remain challenging. This session will discuss advances in the methods of MRD detection in acute myeloid leukemia (AML) and highlight some of the pitfalls.
MRD in AML - Promises, Problems and Perspectives
Eric Duncavage, MD, Washington University, Saint Louis, MO, USA
Objectives:
- Describe different methods used to monitor acute myeloid leukemia following therapy.
- Discuss potential pitfalls associated with these methods.
- Synthesize an integrated approach to monitor therapy response in acute myeloid leukemia.
Duration: 1.00 hr
Recording Date: November 9, 2019
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: December 24, 2022
